Effects of topical dehydroepiandrosterone therapy in women after pelvic organ prolapse surgery
- PMID: 37130371
- DOI: 10.1097/GME.0000000000002183
Effects of topical dehydroepiandrosterone therapy in women after pelvic organ prolapse surgery
Abstract
Objective: Pelvic organ prolapse (POP) occurs predominantly in postmenopausal women. Restoration of the proper estrogenization of vaginal mucosa is important in preoperative and postoperative treatment, increasing the effectiveness of this approach. The objective of this study was the development of intravaginal vaginal suppositories containing DHEA and comparison of the clinical effects of vaginal topical therapy with DHEA, estradiol, or antibiotic after POP surgery.
Method: Nine types of vaginal suppositories containing 6.5 mg DHEA in different bases were prepared to find optimal formulation for the vaginal conditions. Ninety women referred for POP surgery were randomly assigned to one of three groups receiving topical treatment in the postoperative period (estradiol, DHEA, or antibiotic). On admission to hospital and during follow-up vaginal pH, vaginal maturation index and vaginal symptoms were assessed.
Results: Vaginal suppositories with the base made from polyethylene glycol 1,000 without surfactants characterized the highest percentage of the released DHEA. In women treated with topical estradiol or DHEA a significant decrease in the number of parabasal cells, increase in superficial and intermediate cells in the vaginal smears, decrease in vaginal pH, and reduction of vaginal symptoms were observed.
Conclusions: The use of topical therapy with DHEA or the use of topical therapy with estradiol in the postoperative period were both shown to improve maturation index, vaginal pH, and vaginal symptoms. The benefits of topical therapy with DHEA after pelvic organ prolapse repair brings similar results as estradiol, without potential systemic exposure to increased concentrations of sex steroids above levels observed in postmenopausal women.
Copyright © 2023 by The North American Menopause Society.
Conflict of interest statement
Financial disclosures/conflicts of interest: None reported.
Similar articles
-
Does preoperative locally applied estrogen treatment facilitate prolapse-associated symptoms in postmenopausal women with symptomatic pelvic organ prolapse? A randomised controlled double-masked, placebo-controlled, multicentre study.BJOG. 2021 Dec;128(13):2200-2208. doi: 10.1111/1471-0528.16894. Epub 2021 Sep 21. BJOG. 2021. PMID: 34464489 Free PMC article. Clinical Trial.
-
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.Menopause. 2016 Mar;23(3):243-56. doi: 10.1097/GME.0000000000000571. Menopause. 2016. PMID: 26731686 Clinical Trial.
-
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.Menopause. 2018 Nov;25(11):1339-1353. doi: 10.1097/GME.0000000000001238. Menopause. 2018. PMID: 30358731 Clinical Trial.
-
Vaginal Pessaries for Pelvic Organ Prolapse or Stress Urinary Incontinence: A Health Technology Assessment.Ont Health Technol Assess Ser. 2021 May 6;21(3):1-155. eCollection 2021. Ont Health Technol Assess Ser. 2021. PMID: 34055111 Free PMC article.
-
Vaginal DHEA to treat menopause related atrophy: a review of the evidence.Maturitas. 2011 Sep;70(1):22-5. doi: 10.1016/j.maturitas.2011.06.005. Epub 2011 Jul 5. Maturitas. 2011. PMID: 21733647 Review.
References
-
- Weintraub AY, Glinter H, Marcus-Braun N. Narrative review of the epidemiology, diagnosis and pathophysiology of pelvic organ prolapse. Int Braz J Urol 2020;46:5–14. doi: 10.1590/S1677-5538.IBJU.2018.0581 - DOI
-
- Marino JM. Genitourinary Syndrome of Menopause. J Midwifery Womens Health 2021;66:729–739. doi: 10.1111/JMWH.13277 - DOI
-
- Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111(3-5):178–194. doi: 10.1016/J.JSBMB.2008.06.003 - DOI
-
- Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause 2020;27:50–56. doi: 10.1097/GME.0000000000001416 - DOI
-
- Vaccaro CM, Mutema GK, Fellner AN, et al. Histologic and cytologic effects of vaginal estrogen in women with pelvic organ prolapse: a randomized controlled trial. Female Pelvic Med Reconstr Surg 2013;19:34–39. doi: 10.1097/SPV.0B013E318278CC40 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical